Swiss Interactive Media and Services Stock News

SWX:ZURN
SWX:ZURNInsurance

Zurich Insurance Group (SWX:ZURN) Valuation After Strong Earnings And Higher Dividend Announcement

Zurich Insurance Group (SWX:ZURN) has put income and earnings firmly in focus by pairing full year 2025 results with an annual dividend of CHF 30.00 per share, payable on 14 April 2026. See our latest analysis for Zurich Insurance Group. The CHF 580.60 share price has moved higher over the past month with a 1 month share price return of 6.45%, while longer term total shareholder returns of 2.97% over 1 year and 93.42% over 5 years suggest steadily rewarded holders. This points to firm but...
SWX:SPSN
SWX:SPSNReal Estate

Swiss Prime Site’s Valuation After New CHF 350m Green Convertible Bond Issue

Swiss Prime Site (SWX:SPSN) has issued a CHF 350,000,000 zero coupon convertible green bond to refinance existing liabilities and fund eligible sustainable real estate projects within its established framework. See our latest analysis for Swiss Prime Site. The CHF146.70 share price sits against a strong recent run, with a 13.72% 1 month share price return and a 23.80% 3 month share price return, while the 1 year total shareholder return of 45.64% and 3 year total shareholder return of 106.08%...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is It Too Late To Consider Novartis (SWX:NOVN) After Its Strong Multi Year Rally?

If you are wondering whether Novartis shares are still reasonably priced at around their current level, this article walks through what the numbers say about value so you can judge for yourself. With the stock at about US$130.50 and returns of 3.2% over 7 days, 14.3% over 30 days, 20.3% year to date, 38.4% over 1 year, 94.4% over 3 years and 109.0% over 5 years, many investors are asking whether the recent performance already reflects the key positives. Recent coverage around Novartis has...
SWX:SREN
SWX:SRENInsurance

Assessing Swiss Re (SWX:SREN) Valuation After Record 2025 Profit And New Capital Return Plans

Swiss Re (SWX:SREN) is back in focus after reporting a record 2025 profit, along with plans for higher dividends and a sizeable share buyback program, moves that have sharpened market attention on the stock. See our latest analysis for Swiss Re. The record 2025 profit, higher dividend plans and new share buyback have coincided with a 1 month share price return of 11.34% and a 3 day rebound that contrasts with a 90 day share price return decline of 3.96%, while the 5 year total shareholder...
SWX:ISN
SWX:ISNReal Estate

Intershop Holding (SWX:ISN) One Off Gain Challenges Bullish Earnings Momentum Narratives

Intershop Holding FY 2025 results set up a mixed earnings story for investors Intershop Holding (SWX:ISN) has put fresh numbers on the table, with first half FY 2025 revenue of CHF 48.6m and basic EPS of CHF 19.08, against a backdrop of trailing twelve month revenue of CHF 119.1m and EPS of CHF 23.09. The company has seen revenue move from CHF 42.7m in the first half of 2024 to CHF 66.3m in the second half of 2024 and then CHF 48.6m in the first half of 2025, while basic EPS shifted from CHF...
SWX:ABBN
SWX:ABBNElectrical

ABB China AGV Push Tests Robotics Margins And Growth Story

ABB (SWX:ABBN) is expanding its robotics operations in China, with a focus on Automated Guided Vehicles (AGVs) for warehousing and manufacturing. The company is integrating AI and Industry 4.0 technologies into its AGV offerings to support rising automation needs. This expansion reflects ABB's efforts to increase its presence in China's automation and robotics markets. ABB builds robotics and automation solutions for industries that are looking to improve throughput, safety and consistency...
SWX:HOLN
SWX:HOLNBasic Materials

How Holcim’s 2025 Profit Surge Despite Lower Sales At Holcim (SWX:HOLN) Has Changed Its Investment Story

Holcim AG has released its full-year 2025 results, reporting sales of CHF 15,724 million versus CHF 16,201 million in 2024 and net income of CHF 13.18 billion compared with CHF 2.93 billion, alongside sharply higher basic earnings per share of CHF 23.85. The contrast between lower sales and very large growth in net income and earnings per share suggests significant non-operational or one-off effects that investors will want to unpack on the 2025 earnings call held on 27 February 2026. We’ll...
SWX:SDZ
SWX:SDZPharmaceuticals

Sandoz Group (SWX:SDZ) Net Margin Reset To 8.2% Tests Bullish Biosimilar Narrative

Sandoz Group (SWX:SDZ) just wrapped up FY 2025 with second half revenue of US$5.9b, basic EPS of US$1.25 and net income of US$537m. The company has seen revenue move from US$5.3b and a net loss of US$150m in the second half of 2024 to US$5.3b and net income of US$377m in the first half of 2025, before reaching US$5.9b and EPS of US$1.25 in the latest period. This has set up a full year where trailing 12 month net income stands at US$914m and EPS at US$2.12. With a trailing net profit margin...
SWX:FTON
SWX:FTONAuto Components

Feintool International (SWX:FTON) Losses Narrow In H1 2025 Testing Bullish Earnings Turnaround Narrative

Feintool International Holding (SWX:FTON) has kicked off FY 2025 with first half revenue of CHF 334.5 million and a basic EPS loss of CHF 0.34, alongside a net income loss of CHF 5.0 million. The company has seen recent half year revenue move from CHF 390.1 million in the first half of 2024 to CHF 329.5 million in the second half of 2024 and now CHF 334.5 million in the first half of 2025, while EPS shifted from a loss of CHF 0.22 to a loss of CHF 2.78 and now a loss of CHF 0.34. This sets up...
SWX:BYS
SWX:BYSMachinery

Bystronic (SWX:BYS) Margin Repair Story Tested By CHF12.9 Million Half Year Loss

Bystronic (SWX:BYS) has opened FY 2025 with first half revenue of CHF304.6 million and a net income loss of CHF12.9 million, keeping the focus squarely on how quickly the group can turn its earnings profile around. The company has seen revenue move from CHF330.9 million in the first half of 2024 to CHF317.4 million in the second half of 2024 and then to CHF304.6 million in the first half of 2025. Net income losses shifted from CHF20.8 million to CHF46.8 million and then to CHF12.9 million...
SWX:ROG
SWX:ROGPharmaceuticals

Roche’s Giredestrant And Gazyva Data Sharpen Oncology And Nephrology Focus

Roche Holding (SWX:ROG) received FDA acceptance of its New Drug Application for giredestrant in advanced breast cancer. The filing seeks approval for giredestrant in combination therapy for patients with metastatic breast cancer previously treated with CDK4/6 inhibitors. Roche reported positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, a rare kidney disease. Roche, a global pharmaceuticals and diagnostics group, is closely watched for its late stage pipeline...
SWX:UBSG
SWX:UBSGCapital Markets

UBS Group (SWX:UBSG) Valuation Check As Boardroom Shake Up And New US Wealth Leader Take Shape

UBS Group (SWX:UBSG) has announced a series of leadership changes, with new Board nominees Agustín Carstens and Luca Maestri, several long serving directors stepping down, and Lisa Golia taking charge of US wealth management advisers. See our latest analysis for UBS Group. These boardroom changes come as UBS Group’s share price sits at CHF32.01, with a 1 month share price return of 12.95% decline and a year to date share price return of 16.14% decline, even though the 1 year total shareholder...
SWX:BAER
SWX:BAERCapital Markets

Does Julius Bär Gruppe (SWX:BAER) Offer Value After Recent Share Price Softness?

If you are wondering whether Julius Bär Gruppe is fairly priced or offering value right now, the key is to look past the share price and focus on what different valuation methods are actually saying. The stock most recently closed at CHF 65.60, with returns of a 0.5% decline over 7 days, 2.1% over 30 days, a 0.3% decline year to date, 14.3% over 1 year, 21.5% over 3 years and 47.2% over 5 years. This gives you a mix of shorter term softness and longer term gains to weigh. Recent coverage of...
SWX:AVOL
SWX:AVOLSpecialty Retail

Assessing Avolta (SWX:AVOL) Valuation After Breakthrough Shanghai Pudong Duty Free Win

Avolta (SWX:AVOL) has secured the duty free concession at Shanghai Pudong Terminal 1, a rare win for an international travel retailer in mainland China that reshapes investor attention on its China exposure. See our latest analysis for Avolta. The Shanghai Pudong win comes at a time when Avolta’s CHF51.95 share price has a 30 day share price return of 10.63% and a 90 day share price return of 17.75%. Its 1 year total shareholder return of 30.73% contrasts with a 5 year total shareholder...
SWX:EFGN
SWX:EFGNCapital Markets

A Look At EFG International (SWX:EFGN) Valuation After Stable 2025 Earnings And Softer Net Interest Income

EFG International (SWX:EFGN) has attracted fresh attention after reporting full year 2025 results, with net income and earnings per share broadly steady while net interest income declined over the same period. See our latest analysis for EFG International. The earnings release and upcoming March AGM have come after a softer 30 day share price return of 5.22% and a year to date share price return of a 4.83% decline. This is despite the 1 year total shareholder return of 40.71% and 5 year total...
SWX:LOGN
SWX:LOGNTech

A Look At Logitech International’s (SWX:LOGN) Valuation After Management Updates On Demand And Capital Returns

Logitech International (SWX:LOGN) is back in focus after management highlighted firm demand for premium peripherals and enterprise video collaboration, growing China gaming sales, secured memory supply into fiscal 2027, and continued share repurchases and dividend increases. See our latest analysis for Logitech International. At a share price of CHF71.1, Logitech has seen a 2.3% 1 day and 2.3% 7 day share price gain, set against a 90 day share price decline of 21.3% and a 1 year total...
SWX:DKSH
SWX:DKSHTrade Distributors

A Look At DKSH Holding’s (SWX:DKSH) Valuation After Weaker 2025 Earnings And Boardroom Changes

DKSH Holding (SWX:DKSH) has drawn fresh attention after reporting full year 2025 earnings, which showed slightly lower sales and net income, along with board changes and a confirmed CHF 2.50 per share annual dividend. See our latest analysis for DKSH Holding. Against this backdrop, DKSH Holding’s 30 day share price return of 9.28% and 90 day share price return of 11.23% contrast with a 1 year total shareholder return of 9.53% and 3 year total shareholder return of 12.13%. This suggests recent...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis Expands US Radioligand Network With New Denton Cancer Facility

Novartis (SWX:NOVN) plans to build a new radioligand therapy manufacturing facility in Denton, Texas. The plant will expand US production capacity for next generation cancer treatments. The project is expected to create specialized jobs and support a more resilient domestic supply chain. For you as an investor, this move highlights how Novartis is leaning further into radioligand therapies, a targeted cancer treatment area that has drawn growing interest in oncology. The Denton site adds to...
SWX:AMRZ
SWX:AMRZBasic Materials

Amrize Resets Audit Oversight As Investors Assess Governance And Reporting

Amrize (SWX:AMRZ) has appointed Ernst & Young LLP (EY US) as its new independent registered public accounting firm, moving from EY Switzerland. The company has reshaped its board structure, including naming a new Chair for the Audit Committee and adding a board member with audit expertise. These governance changes focus on audit oversight, internal controls and financial reporting processes. For investors watching Amrize at a share price of CHF49.27, the shift to EY US and the refreshed...
SWX:SCHN
SWX:SCHNMachinery

What Schindler Holding (SWX:SCHN)'s Higher Earnings And CHF 6.00 Dividend Means For Shareholders

Schindler Holding AG has reported full-year 2025 results, with sales of CHF 10,947 million and net income of CHF 1,015 million, and has approved an annual dividend of CHF 6.00 per share payable on March 30, 2026. The combination of higher net income and earnings per share, despite slightly lower sales, alongside the confirmed cash return to shareholders, underlines the group’s ability to convert revenue into profit and maintain shareholder distributions. Against this backdrop of higher...
SWX:ALSN
SWX:ALSNElectronic

Assessing ALSO Holding (SWX:ALSN) Valuation After 2025 Results And Higher Dividend

Earnings and dividend move into focus ALSO Holding (SWX:ALSN) reported full year 2025 results with sales of €13,501.23m and net income of €109.33m, alongside a higher annual dividend of CHF 5.30 per share. See our latest analysis for ALSO Holding. The earnings release, dividend increase and earnings call arrived after a tough stretch for shareholders, with the 1 year total shareholder return at a 40.5% loss and the year to date share price return at a 24.7% loss. However, the 7 day share...
SWX:GF
SWX:GFMachinery

Georg Fischer (SWX:GF) EPS Jump On Softer Revenue Tests Bullish Margin Narratives

Georg Fischer FY 2025 earnings snapshot Georg Fischer (SWX:GF) has opened FY 2025 with first half revenue of CHF2.3b and basic EPS of CHF1.95, alongside net income excluding extra items of CHF160m, setting a clear marker for its latest performance. The company has seen first half revenue shift from CHF1.96b in 2023 to CHF2.41b in 2024 and then to CHF2.26b in 2025, while basic EPS moved from CHF1.50 to CHF1.18 and then to CHF1.95 over the same periods. This gives investors a clearer view of...
SWX:SDZ
SWX:SDZPharmaceuticals

Assessing Sandoz Group (SWX:SDZ) Valuation After Strong 2025 Results And Biosimilar Growth Milestones

Sandoz Group (SWX:SDZ) has drawn fresh attention after reporting full year 2025 earnings, with sales of US$11,086 million and net income of US$914 million, alongside progress in its expanding biosimilars portfolio. See our latest analysis for Sandoz Group. Sandoz Group's 1 day share price return of 2.87% contrasts with a 7 day share price return of 4.64% and a 90 day share price return of 24.01%. The 1 year total shareholder return of 80.41% points to strong momentum around its biosimilars...
SWX:WKBN
SWX:WKBNBanks

Walliser Kantonalbank (SWX:WKBN) Margin Compression Reinforces Bearish Valuation Narratives

Latest earnings snapshot Walliser Kantonalbank (SWX:WKBN) has just posted FY 2025 numbers, with first half revenue of CHF 135.7m and net income (excluding extra items) of CHF 61.0m. This helps indicate how its profitability is holding up. The bank has seen revenue move from CHF 140.7m in 1H 2024 to CHF 154.1m in 2H 2024, and then to CHF 135.7m in 1H 2025. Over the same periods, net income shifted from CHF 66.0m to CHF 69.4m, and then to CHF 61.0m. These figures give investors a clearer view...